This video compares Moderna’s recent Phase 3 win in personalized mRNA cancer therapy to BioNTech’s wider oncology pipeline.

Add Yahoo as a preferred source to see more of our stories on Google. An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning ...

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.

Click here for the report explaining the August 24th YouTube video!Large-scale clinical trial data has been released regarding the combination therapy of the personalized cancer vaccine ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CNBC’s Annika Kim Constantino joins 'Squawk on the Street' to discuss the FDA approving Moderna's mRNA flu vaccine. Got a confidential news tip? We want to hear from you. Sign up for free newsletters ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at ...

Now, it’s worth noting Stock Advisor’s total average return is 951 % — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Interim analysis shows goals were met for recurrence and preventing cancer spread Moderna spikes as much as 160%; Merck jumps 12% Barclays estimates therapy could reach about $3 billion in melanoma ...